Reprints and permissions information is available at http://www.nature.com/reprints. ArticleC 0102030405060708090100 Percentag eGrade 1 Safety of atezolizumab (n = 19 evaluable patients) Grade 2 Pruri tisRash Alopec iaFeve rBone pa inEdemaDiarrhea Thrombo embolismParesthesiaFlu-like symptomsFatigu eChillsFeverFatigueDiarrh eaEdemaAnorexia Dyspne aInfusio n reactionAnemiaAlopecia Hypertensio nVomitingSafety of autogene cevumeran (n = 16 evaluable patients) Any adverse eventThromb oembolis mA Age at diagnosis (y) Median (range) 68 (55-80) Mean ± SD 68 ± 8.1 Sex Male 9 (47) Female 10 (53) Race/ethnicity White 19 (100) Black 0 (0) Asian 0 (0) Unknow n 0 (0) Tumor location Head 11 (58) Body/tail 8 (42) Primary tumor size (cm) Mean ± SD 2.8 ± 0. 9 Median (range) 2.6 (1.0-4.2 ) Surgical procedur e Pancreaticoduodenectomy 11 (58) Distal pancreatectomy with splenectomy 8 (42) Arterial/venous involvement Yes 3 (16) No 16 (84) Pathology Stage I 5 (26) Stage II 8 (42) Stage III 6 (32) Surgical margin R0 16 (84) R1 3 (16) Any adverse even t0102030405060708090100 Percentag eAll evaluable patients (safety evaluable + biomarker evaluable )B Characteristic Resp onders (n = 8) Non-responders (n = 8) P value Age at diagno sis (y) Median (range ) 70.5 (59-80 )7 1.5 (55-76 ) 0.6 Mean ± SD 70.5 ± 8.3 71.5 ± 7.8 Sex Female 6 (75) 2 (25) 0.1 Male 2 (25) 6 (75) Race/ethni city White 8 (100 ) 8 (100) NA Black 0 (0) 0 (0) Asian 0 (0) 0 (0) Unknow n 0 (0) 0 (0) Tumor location Head 6 (75) 3 (37.5) 0.3 Body/ta il 2 (25) 5 (62.5) Primary tumor si ze (cm) Median (range ) 2.3 (1 .0-2.9 )3 (1.9-4.2 ) 0.04 Mean ± SD 2.2 ± 0.6 3.2 ± 0.9 Surgical procedur e Pancreatoduodenectomy 6 (75) 3 (37.5) 0.3 Distal pancreatectomy with sple nectom y 2 (25) 5 (62.5) Arterial/venous involv ement >0.99 Yes 2 (25) 1 (12.5) No 6 (75) 7 (87.5) Patholog y Stage I 4 (50) 1 (12.5) 0.3 Stage II 3 (37.5) 4 (50) Stage III 1 (12.5) 3 (37.5) Surgical margin R0 6 (75) 7 (87.5) >0.99 R1 2 (25) 1 (12.5) Lymph node status N0 4 (50) 2 (25) 0.6 N1/N 2 4 (50) 6 (75) Atezolizumab response Yes 4 (50) 5 (62.5) >0.99 No 4 (50) 3 (37.5) Biomarker evaluable patients Characteristic Extended Data Fig. 1 | Patient demographics, clinical characteristics, and toxicity. (A, B ) Demographics and clinical characteristics of all evaluable patients ( n = 19) ( A) and biomarker-evaluable patients ( n = 16) stratified by autogene cevumeran responders and non-responders ( B). (C) Frequency of grade 1 and 2 adverse events attributable to atezolizumab ( left ) and vaccine (right ) in evaluable patients who received each drug. n = individual patients.